Benzinga | Jan 22, 2021 06:10AM EST

BMO Capital Downgrades Sage Therapeutics to Market Perform, Announces $95 Price Target

BMO Capital analyst Gary Nachman downgrades Sage Therapeutics (NASDAQ:SAGE) from Outperform to Market Perform and announces $95 price target.